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Abstract 15 
Neisseria gonorrhoeae is one of the leading antimicrobial resistance threats worldwide and there 16 
is a need for the development and evaluation of new antimicrobials. The aims of this study were 17 
to determine the in vitro susceptibility to the novel antimicrobial closthioamide (CTA) of clinical 18 
Neisseria gonorrhoeae strains, reference N. gonorrhoeae strains and related commensal 19 
Neisseria species. Minimum inhibitory concentration (MIC) to CTA and six antibiotics were 20 
determined using agar dilution for 149 clinical N. gonorrhoeae, eight World Health Organisation 21 
reference N. gonorrhoeae and four commensal Neisseria species. The correlation between CTA 22 
MICs and ciprofloxacin, penicillin, cefixime, ceftriaxone, azithromycin and tetracycline were also 23 
determined using Spearman’s Rank correlation test. CTA MIC for the clinical and reference 24 
gonococcal strains were 0.008-0.25 mg/L and 0.063-0.5 mg/L respectively. The MIC range for 25 
commensal species was 0.063-1 mg/L. The MIC50 and MIC90 of the clinical gonococcal strains 26 
were 0.063 mg/L and 0.125 mg/L respectively. The MICs of CTA did not correlate with the MICs 27 
of the other antibiotics tested. Closthioamide has high in vitro activity against N. gonorrhoeae and 28 
cross-resistance due to existing antimicrobial resistance was not detected, indicating that CTA 29 
could be used to treat drug-resistant infections. However, further research on the mechanism of 30 
action, toxicity, pharmacokinetics and pharmacodynamics of CTA need to be conducted to 31 
evaluate the clinical suitability of this antimicrobial.  32 
 33 
 34 
  35 
Introduction 36 
Neisseria gonorrhoeae is one of the most important antimicrobial resistance (AMR) threats 37 
worldwide(1). The discovery of penicillin in the 1940s revolutionised the treatment of N. 38 
gonorrhoeae however resistance has developed to every therapeutic antimicrobial agent 39 
used(2). In the past 15 years empirical therapy in the UK has had to be changed three times due 40 
to increasing rates of resistance, on average every five years(3).  41 
Dual therapy for gonorrhoea, with ceftriaxone and azithromycin, was introduced in 2011(4) as a 42 
strategy to delay AMR. These antibiotics represent the last reliable classes of antibiotics 43 
recommended for empirical treatment of N. gonorrhoeae infection(5) and worryingly, the 44 
minimum inhibitory concentration (MIC) to both antibiotics are increasing annually(6). This is 45 
complicated further by reports of treatment failure due to extended spectrum cephalosporin 46 
(ESC) resistance occurring worldwide(7–16).  In 2016, treatment failure occurred after dual 47 
therapy with ceftriaxone and azithromycin in a UK patient with urethral and pharyngeal 48 
infection(17). Phenotypic and molecular AMR testing indicated that the gonococcal isolate was 49 
resistant to both agents, providing challenging prospects for the future treatment of gonorrhoea.  50 
In 2012, the World Health Organisation (WHO) published an action plan to combat the spread 51 
and impact of N. gonorrhoeae(1). Given that there is no effective vaccine against gonorrhoea 52 
and antimicrobial therapy is still one the most important means of gonorrhoea control, the WHO 53 
advocates research into new antimicrobials(1). 54 
Closthioamide, discovered in 2010, was isolated from the anaerobic bacterium Clostridium 55 
cellulolyticum(18). It represents a new class of natural polythioamide antibiotics and has been 56 
shown to have high in vitro activity against AMR microorganisms such as methicillin resistant 57 
Staphylococcus aureus (MRSA) and vancomycin resistant Enterococci (VRE)(19). Its mode of 58 
action is not yet well understood but there is evidence it may impair DNA replication and inhibit 59 
DNA gyrase(19). Cross-resistance to quinolone antibiotics has not been observed to-date, 60 
suggesting a different mechanism of action(19). Given its high potency with multi-drug resistant 61 
(MDR) bacteria, closthioamide is a candidate antibiotic to test against N. gonorrhoeae. 62 
The aim of this study is to determine the in vitro activity of closthioamide against clinical and 63 
laboratory reference strains of N. gonorrhoeae, as well as commensal Neisseria species.  64 
 65 
Results 66 
Bacterial Isolates 67 
A total of 149 clinical N. gonorrhoeae isolates were examined in this study; 97 isolates were 68 
obtained from Barts Health NHS Trust, 50 from St George’s University Hospitals NHS 69 
Foundation Trust and one each from Royal Free NHS Foundation Trust and Tunbridge Wells 70 
NHS. The gonococcal isolates were cultured from pharyngeal (n=11, 7.4%), urethral (n=19, 71 
12.7%), cervical (n=3, 2%) or rectal (n=19, 12.7%) infection and 65% (n=97) had an unknown 72 
site. 73 
 74 
CTA susceptibility 75 
The MICs for the novel antibiotic closthioamide were determined for 149 clinical gonococcal 76 
isolates, eight reference gonococcal isolates and four commensal Neisseria species. Of the 149 77 
clinical strains, 131 had previously determined MICs to penicillin, ceftriaxone, azithromycin, 78 
ciprofloxacin, tetracycline and spectinomycin and 127 had known MICs to cefixime.  79 
The CTA MIC range of the 149 clinical strains was between 0.008 mg/L – 0.25 µmg/L. The 80 
number of isolates with MICs of 0.008 mg/L, 0.015 µmg/L, 0.031 µmg/L, 0.063 mg/L, 0.125 mg/L 81 
and 0.25 mg/L were one (1%), six (4%), 14 (9%), 53 (36%), 72 (48%) and three (2%) 82 
respectively (Figure 1). The MIC50 and MIC90 were 0.063 mg/L and 0.125 mg/L respectively.  83 
The CTA MICs of N. lactamica and N. perflava were 0.063 mg/L and 0.5 mg/L respectively and 84 
both N. flavescens strains had an MIC of >1 mg/L. The CTA MICs of the WHO gonococcal 85 
control strains were higher than the MIC50 of the clinical strains and the MIC of WHO strain K 86 
was 0.5 mg/L, higher than any of the clinical strains (Table 1).  87 
 88 
Cross-resistance to CTA 89 
The MICs for seven antibiotics were compared to CTA MICs to identify any cross-resistance. 90 
Resistance rates, using WHO breakpoints (Table 1)(20), for the clinical gonococcal strains for 91 
penicillin, cefixime, ceftriaxone, azithromycin, ciprofloxacin, tetracycline and spectinomycin were 92 
7.6% (10/131), 2.4%(3/127), 0.8%(1/131), 0.8% (1/131), 23.7%(31/131), 15.3%(20/131) and 0% 93 
(0/131) respectively. No significant correlation was identified between the tested antibiotics; 94 
ciprofloxacin, a fluoroquinolone, had a correlation coefficient of 0.07 (Figure 2, Table 2), the 95 
highest correlation was 0.48 with azithromycin.  96 
 97 
Discussion 98 
The imminent threat of untreatable gonorrhoea is a global problem that urgently requires the 99 
development of new antimicrobial agents. In this study, the novel antimicrobial closthioamide was 100 
evaluated against 149 clinical and eight reference strains of N. gonorrhoeae and four commensal 101 
Neisseria species. CTA was effective in vitro against 146/149 (98%) of clinical gonococcal strains 102 
at ≤0.125mg/L, suggesting a low therapeutic dose concentration which would reduce any 103 
potential toxicity. Importantly isolates resistant to ciprofloxacin and the first line therapeutic 104 
agents ceftriaxone and azithromycin are as susceptible to CTA as strains sensitive to these 105 
antibiotics, suggesting CTA could be effective clinically against MDR N. gonorrhoeae strains.  106 
Closthioamide activity against N. gonorrhoeae is comparable to its activity against other AMR 107 
organisms; N. gonorrhoeae MIC90 (0.125mg/L) was higher than for MRSA (0.027mg/L) but lower 108 
than for VRE (0.44mg/L)(19). This is noteworthy, as previous studies have shown CTA to be 109 
more effective in vitro against Gram-positive organisms than Gram-negative organisms such as 110 
E. coli where the MIC ranges between 0.31 mg/L. and 3.75 mg/L(19).  111 
CTA mode of action has been linked to gyrase and DNA replication which is also a target for 112 
fluoroquinolones suggesting a potential cross-resistance with antibiotics such as ciprofloxacin. 113 
Analysis of the WHO reference strains demonstrated that although Strain K had the highest CTA 114 
MIC (0.5mg/L) and resistance to ciprofloxacin (>32 mg/L) due to gyrase mutations(21); Strain L, 115 
with equal ciprofloxacin resistance, was still sensitive to CTA. Analysis of the clinical isolates 116 
demonstrated no correlation between the two antibiotics. This is also supported by a study by 117 
Chiriac et al who found no cross-resistances between the two antimicrobials, although they did 118 
not examine N. gonorrhoeae(19). These data suggests that CTA susceptibility is not linked to 119 
fluoroquinolone resistance, as mutations in the gyrA region which confer resistance to 120 
fluoroquinolone do not seem to influence CTA MICs, indicating that the active site for CTA may 121 
be elsewhere in the quinolone resistance determining region (QRDR). 122 
Interestingly, the two N. perflava strains had the highest CTA MIC (>1 mg/L) and the basis of this 123 
relative resistance requires further research to understanding the specific resistance 124 
mechanisms.  125 
Closthioamide has been shown to have low toxicity in tissue culture(19), making it a good 126 
candidate for clinical use, however further work should be carried out in terms of its toxicity, 127 
pharmacokinetics and pharmacodynamics(22). Successful treatment of pharyngeal infection is 128 
critical to the gonorrhoea control efforts(23–25) meaning that penetration of any new 129 
antimicrobial into the pharyngeal mucosa is of particular importance. Clinical trials investigating 130 
the efficacy of existing antimicrobials such as gentamicin are currently being carried out(26), 131 
however these agents have poor pharyngeal penetration and even if successful will not offer a 132 
long term solution, as development of resistance to aminoglycosides occurs readily(27). 133 
In conclusion, CTA has high anti-gonococcal activity in vitro, even for multidrug resistant isolates, 134 
but further studies to evaluate the clinical potential of this antimicrobial are urgently required in 135 
light of the public health threat that gonorrhoea poses. 136 
 137 
Materials & Methods 138 
Bacterial Isolates 139 
Clinical, anonymised Neisseria gonorrhoeae isolates cultured from patients at Barts Health NHS 140 
Trust, St George’s University Hospitals NHS Foundation Trust, Royal Free NHS Foundation 141 
Trust and Tunbridge Wells NHS Trust hospital laboratories during the period 2013-2014 were 142 
examined in this study.  Eight fully characterised WHO gonococcal reference strains, F, G, K, L, 143 
M, N, O and P were provided by the Sexually Transmitted Bacteria Reference Unit (STBRL), 144 
Public Health England (PHE), UK. Commensal Neisseria lactamica (n=1), Neisseria perflava 145 
(n=1) and Neisseria flavescens (n=2) were provided by the London School of Hygiene & Tropical 146 
Medicine (LSHTM) and the Royal Free NHS Foundation Trust Microbiology Laboratory. Isolates 147 
were preserved in 20% glycerol Brain Heart Infusion (BHI) broth at -80oC. Prior to MIC testing, 148 
isolates were cultured on Columbia agar supplemented with chocolated horse blood (Oxoid, 149 
Basingstoke, UK) at 37oC, in 5% CO2 for 24 hours.  150 
 151 
Antimicrobial Susceptibility Testing 152 
The MICs for CTA, cefixime, ceftriaxone, spectinomycin, tetracycline and azithromycin were 153 
determined by the agar dilution method, as previously described(20). A multi-point inoculator 154 
(Denley, Colchester, UK) was used to inoculate 1μl of each suspension onto each plate in the 155 
respective antimicrobial agar dilution series. The CTA MIC range tested was 0.002 mg/L - 1 156 
mg/L. The MICs for penicillin and ciprofloxacin were determined via gradient strip (Launch 157 
Diagnostics, Kent, UK and Biomerieux, Crappone, France respectively) as previously 158 
described(20).  159 
 160 
Synthesis of CTA 161 
Closthioamide was synthesized according to the route of Hertweck and coworkers(28, 29). 162 
Closthioamide stock solution was prepared at 100 mg/L in 100% ethanol. The core of CTA was 163 
synthesized by two consecutive peptide couplings and deprotections onto a 1,3-diaminopropane 164 
core with an N-protected beta-alanine, followed by a third peptide coupling to install the aromatic 165 
benzoic acid end caps. Thionation (oxygen to sulphur converson) with Lawesson’s reagent and 166 
deprotection under highly acidic conditions yielded CTA in five longest linear steps. It was noted 167 
during purification of CTA that ethanol present in the chloroform solvent as a stabilizer was 168 
retained. 169 
All reagents involved in the synthesis of intermediates, peptide coupling, protection/deprotection 170 
and synthesis of CTA were obtained from Sigma-Aldrich, with the exception of 1-ethyl-3-(3-171 
dimethylaminopropyl)carbodiimide (EDCI) from Manchester Organics. All reaction solvents used 172 
in synthesis were anhydrous and of the highest grade from Sigma-Aldrich. All routine solvents for 173 
workup and purification were obtained from VWR. In all cases, reagents and solvents were used 174 
as received. 175 
 176 
Statistical analysis 177 
Data were analysed in Microsoft Excel. MIC50 and MIC90 were calculated with MIC data from 178 
clinical gonococcal strains only. The correlation between CTA MICs and those for other 179 
antibiotics was determined with a Spearman’s Rank correlation test, using STATA 14.2. The 180 
correlation coefficient was calculated using MIC data from clinical and reference gonococcal 181 
strains. 182 
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 281 
TABLES AND FIGURES LEGENDS  282 
 283 
Figure 1. Susceptibility of gonococcal isolates to closthioamide (CTA).  284 
CTA was tested on 149 clinical gonococcal strains (range tested was 0.002 – 1 mg/L). MIC = 285 
Minimum Inhibitory Concentration. 286 
 287 
 288 
Table 1. MICs of WHO gonococcal reference strains. Minimum inhibition concentration (MICs) 289 
(mg/L) determined by World Health Organisation (WHO) for penicillin (PEN), cefixime (CFX), 290 
ceftriaxone (CRO), azithromycin (AZI), ciprofloxacin (CIP), tetracycline (TET), spectinomycin 291 
(SPE). Closthioamide (CTA) MIC was determined by agar dilution in this study.  292 
 293 
 294 
Figure 2. Correlation between CTA and ciprofloxacin MICs. MIC data for CTA and 295 
ciprofloxacin from 139 clinical strains was used to calculate a correlation coefficient (R2) of 0.07. 296 
 297 
 298 
Table 2. Raw data showing number of clinical isolates with given combination of CTA and 299 
Ciprofloxacin MICs.  300 
 301 
 302 
 
